The average one-year price target for Replimune Group (NasdaqGS:REPL) has been revised to $12.82 / share. This is an increase of 10.52% from the prior estimate of $11.60 dated November 14, 2025. The ...

The latest price target for Replimune Group (NASDAQ:REPL) was reported by BMO Capital on November 3, 2025. The analyst firm set a price target for $11.00 expecting REPL to rise to within 12 months (a ...

Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...

It was the subject of a recommendation downgrade from an analyst. Another pundit reiterated his neutral stance on the company. Rama based much of his new take on the company on the latest developments ...

Shares of Replimune (NASDAQ:REPL) plunged ~38% in the premarket on Monday after Stat News reported that the FDA’s top regulator of cancer drugs intervened during the review of the company’s lead asset ...

Despite a sharp drop in the previous session following the FDA rejection of its skin cancer drug RP1, Replimune (NASDAQ:REPL) shares bounced back on Wednesday even as multiple Wall Street analysts ...

On June 11, 2025, the Python core team released Python 3.13.5, the fifth maintenance update to the 3.13 line. This release is not about flashy new language features, instead, it addresses some ...

In this tutorial, we will discover how to harness the power of an advanced AI Agent, augmented with both Python execution and result-validation capabilities, to tackle complex computational tasks. By ...

REPLIMUNE GROUP ($REPL) posted quarterly earnings results on Thursday, May 22nd. The company reported earnings of -$0.82 per share, missing estimates of -$0.77 by $0. ...

A young computer scientist and two colleagues show that searches within data structures called hash tables can be much faster than previously deemed possible. Sometime in the fall of 2021, Andrew ...